TB-500 10mg

TB-500 – Product Information

TB-500 is a synthetic replica of Thymosin Beta 4, a protein peptide that occurs naturally in the bodies of both animals and humans. In horse racing, TB-500 is shown to have a significant effect on the reduction of inflammation and the inhibition of adhesions from injury. In a rat full-thickness wound model, TB-500 exhibited potent wound-healing effects. Wounds treated topically with TB-500 showed an 18% decrease in gap compared with saline-treated control wounds as early as 4 days after injury. They also contracted at least 7% more than controls by day 7.

What is TB-500?

As stated earlier, TB 500 is a man-made replica of TB-4, a peptide found naturally in human and animal cells. Thymosin Beta 4 plays a pivotal role in increasing angiogenesis (formation of new blood vessels) in dermal tissues. TB-500, like Thymosin Beta 4, consists of 43 amino acids. This synthetic peptide was originally developed for veterinary purposes and is claimed to offer various therapeutic benefits to a racehorse. Such claims led to the development of a testing procedure to detect the use of this compound in equines. We sell TB-500 for laboratory research use only.

How does TB-500 Work?

TB-500 up-regulates the action of actin and blocks actin polymerization in eukaryotic cells. Actin is a cell-building protein that promotes cell migration and proliferation. It plays a pivotal role in muscle contraction as well as in cell differentiation and helps with tissue repair and regeneration. TB-500 has also been shown to promote angiogenesis or blood vessel formation, likely through the Notch signaling pathway. In a rat study, the TB-4 treated group showed increased expression of genes associated with angiogenesis than the control group.

TB-500 Vs. BPC-157

TB-500 and BPC 157 are both synthetic peptides. TB-500, as stated above, is a synthetic form of TB-4, a regenerative compound found in the majority of tissues and circulating cells in the body. In vivo and in vitro testing has shown that TB-4 could alleviate premature cell death or apoptosis of tubular endothelial cells. BPC 157, meanwhile, is a partial sequence of the body protection compound found in human gastric juices. It has been shown to be safe in clinical trials for treating inflammatory bowel disease (IBD). Additionally, a 2003 study found that BPC 157 improved burn healing in mice.

TB-500 Research

Various test-tube or animal studies have been conducted on TB-500/Thymosin Beta 4. The results obtained from these studies point to promising research applications for heart health, wound healing, tissue repair, and muscle tissue growth. Keep in mind that much of the research has been conducted on TB-4, the parent molecule and naturally occurring version of synthetic TB-500. However, since TB-500 is chemically and structurally identical to TB-4, they should offer the same effects on research subjects.

TB-500 and Heart Health

In a clinical phase 2 trial, TB-4 was found to reduce the volume of scars after a heart attack. The trial was conducted on patients with acute myocardial infarction (MI), the leading cause of cardiac death worldwide. It was confirmed that TB-4 could protect and repair the heart. In an animal study, TB-4 treatment improved left ventricular function and reduced cardiac remodeling after myocardial infarction. Treated animals showed higher levels of CD73 activity and chitinase 3-like-1, novel molecules possibly related to TB-4 mediated cardio-protection. Lastly, a study has highlighted multiple functions TB-4 plays in the protection, repair, and regeneration of the mammalian heart. It has been shown to promote cell survival, modulate the ischemic heart’s inflammatory environment, and reactivate the dormant epicardium.

TB-500 and Duchenne Muscular Dystrophy

In a mouse model of Duchenne muscular dystrophy (DMD), the effects of chronic TB-4 administration on skeletal and cardiac muscle were studied. DMD is characterized by weakness and wasting of the pelvic area muscles. As the disease spreads, the trunk and forearms are affected. TB-4 treated mice showed a significant increase in skeletal muscle regenerating fibers compared to untreated mice. Based on these results, chronic TB-4 administration could have a potential role in the treatment of skeletal muscle disease in Duchenne muscular dystrophy.

TB-500 and Muscle Growth

Thymosin Beta 4 was acutely increased in the plasma of exercising humans irrespective of the insulin resistance condition or exercise mode, notes a study published in the November 2021 edition of the American Journal of Physiology. Treatment of mice with TB-4 didn’t ameliorate the metabolic disruptions associated with diet-induced obesity. Nor did it enhance muscle regeneration. However, TB-4 increased osteoblast proliferation and neurite outgrowth, consistent with its WADA classification as a prohibited growth factor. Furthermore, a cell-based study found that muscle injury enhances the location production of Thymosin Beta 4, thereby promoting the migration of myoblasts to facilitate skeletal muscle regeneration.

TB-500 and Rheumatoid Arthritis

A study published in 2017 discussed the logical and clinical justifications for Thymosin Beta 4 as a potential target for rheumatoid arthritis (RA) therapeutics. It was shown that there were increased TB-4 levels in serum and joint fluid in patients with RA. In conclusion, whether increased TB-4 expression in serum and joint fluid in RA patients is beneficial or harmful remains to be elucidated.

TB-500 and Wound Healing

According to scientific papers presented at the 7^th International Congress of Allergy and Immunology, TB-4 markedly accelerated wound healing in the eye. It does that by increasing epithelial migration and reducing inflammation. Both are important for more rapid and complete healing. Data from another study demonstrate that recombinant TB-4 can promote full-thickness cutaneous wound healing in mice. Treatment with Thymosin Beta 4 also resulted in increased re-epithelialization and considerable capillary growth.

TB-500 and Diabetes

Thymosin Beta 4 ameliorates hyperglycemia and improves insulin in a mouse model of type 2 diabetes mellitus (T2DM). TB-4 also improved glucose intolerance in KK mice. It may be a potential alternative insulin sensitizer for the treatment of type 2 diabetes mellitus. Another study was conducted to investigate the efficacy and safety of TB-4 treatment for peripheral neuropathy, which is a chronic complication of diabetes mellitus. The data demonstrated that TB-4 treatment ameliorates diabetic-induced axonal degeneration and demyelination. This may likely contribute to the therapeutic effect of TB-4 on diabetic neuropathy.

TB-500 and Liver Injury

A rodent study was conducted to investigate the effects of exogenous TB-4 on carbon tetrachloride (CCI4)-induced liver injury and fibrosis. Histopathological examinations indicated that CCI4 induced collagen deposition in rats’ livers and extensive necrosis in mice livers. However, all these changes in mice and rats were significantly attenuated by exogenous TB-4 treatment. Taken together, findings in this study suggested that exogenous TB-4 might prevent CCI-4 acute liver injury and subsequent fibrosis.